Light-chain shuffling results in successful phage display selection of functional prokaryotic-expressed antibody fragments to N-glycolyl GM3 ganglioside

Rojas, Gertrudis; Talavera, Ariel; Muñoz, Yasmiana; Rengifo, Enrique; Krengel, Ute; Ångström, Jonas; Gavilondo, Jorge V.; Moreno, Ernesto

doi:10.1016/j.jim.2004.07.002

Cited by 30 publications

(51 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kim and Hong reported about an enhancement of affinity of a humanized monoclonal antibody after light chain shuffling (Kim and Hong 2007). For allergen-specific human IgE antibodies there is some evidence that the heavy chain determines allergen-specificity (Laffer et al 2001;Rojas et al 2004;Christensen et al 2009;Gadermaier et al 2010b). It is therefore quite possible, that the affinity of allergen-specific antibodies can be increased by shuffling of light chains.…”

Section: Affinitymentioning

confidence: 99%

Passive Immunization with Allergen-Specific Antibodies

Flicker

Gadermaier

Madritsch

et al. 2011

Vaccines Against Allergies

View full text Add to dashboard Cite

The induction of allergen-specific IgG antibodies has been identified as a major mechanism responsible for the reduction of allergic inflammation in allergic patients treated by allergen-specific immunotherapy. Several studies suggest that allergen-specific IgG antibodies induced by vaccination with allergens block mast cell and basophil degranulation, IgE-facilitated allergen presentation to T cells and IgE production. The availability of recombinant allergens and technologies for the production of recombinant human antibodies allows engineering of allergen-specific antibodies which can be used for passive immunization (i.e., therapy) and eventually for the prevention of allergy (i.e., prophylaxis). This chapter summarizes data supporting the possible use of allergen-specific antibodies for treatment and prophylaxis. Finally, concrete approaches for the treatment and prevention of allergy based on blocking antibodies are envisioned.

show abstract

Section: Affinitymentioning

confidence: 99%

Passive Immunization with Allergen-Specific Antibodies

Flicker

Gadermaier

Madritsch

et al. 2011

Vaccines Against Allergies

View full text Add to dashboard Cite

show abstract

“…To probe if hypoxia also triggers increased expression of NeuGc GM3 in HeLa cells, flow cytometry experiments were performed. For detection, we used the murine antibody 14F7, which specifically recognizes NeuGc GM3 and can discriminate it from the very similar NeuAc derivative [20,[37][38][39]. This antibody was earlier subjected to glycoarray screening by the Functional Glycomics Consortium (www.functionalglycomics.org), with negative results, even for the NeuGc GM3 trisaccharide (data not shown), indicating that it is indeed very specific and furthermore requires the ganglioside's sphingolipid part for antigen recognition.…”

Section: Resultsmentioning

confidence: 99%

Hypothesis: Hypoxia inducesde novosynthesis of NeuGc gangliosides in humans through CMAH domain substitute

Bousquet

Sandvig

Edin

et al. 2017

Preprint

Self Cite

View full text Add to dashboard Cite

Immunotherapy is a growing field in cancer research. A privileged tumor-associated antigen that has received much attention is N-glycolyl (NeuGc) GM3. This ganglioside is present in several types of cancer, but is almost undetectable in human healthy tissues. However, its non-hydroxylated variant, NeuAc GM3, is abundant in all mammals. Due to a deletion in the human gene encoding the key enzyme for synthesis of NeuGc, humans, in contrast to other mammals, cannot synthesize NeuGc GM3. Therefore the presence of this ganglioside in human cancer cells represents an enigma. It has been shown that hypoxic conditions trigger the expression of NeuGc gangliosides, which not only serve as attractive targets for cancer therapy, but also as diagnostic and prognostic tumor marker. Here, we confirm hypoxia-induced expression of the NeuGc GM3 ganglioside also in HeLa cells and reveal several candidate proteins, in particular GM3 synthase and subunit B of respiratory complex II (SDHB), that may be involved in the generation of NeuGc GM3 by SILAC-based proteome analysis. These findings have the potential to significantly advance our understanding of how this enigmatic tumor-associated antigen is produced in humans, and also suggest a possible mechanism of action of anti-tumor antibodies that recognize hypoxia markers, such as 14F7.

show abstract

“…25,31 Soluble antibody fragments from the selected clones were usually produced by induction with IPTG in the absence of helper phage. 32 In the present study, the supernatant of lysate was used for the identification of the positive clones.…”

Section: Discussionmentioning

confidence: 99%

Isolating human antibody against human hepatocellular carcinoma by guided-selection

Bao¹,

Yu²,

Ma³

et al. 2005

Cancer Biology & Therapy

View full text Add to dashboard Cite

Light-chain shuffling results in successful phage display selection of functional prokaryotic-expressed antibody fragments to N-glycolyl GM3 ganglioside

Cited by 30 publications

References 39 publications

Passive Immunization with Allergen-Specific Antibodies

Passive Immunization with Allergen-Specific Antibodies

Hypothesis: Hypoxia inducesde novosynthesis of NeuGc gangliosides in humans through CMAH domain substitute

Isolating human antibody against human hepatocellular carcinoma by guided-selection

Contact Info

Product

Resources

About